Dr Das presents the ABSORB II trial, the first-in-man study comparing BRS to Xience stents. Powered for two primary endpoints:
- Superiority of Absorb over Xience in coronary vasomotion
- Non-inferiority against Xience in late loss
Whilst some data remains encouraging, the trial has highlighted important areas of concern that require further thought, outlined in this excellent summary talk.